NASDAQ · DOMH
Dominari Holdings Inc.
$1.72-$0.03 (-1.71%)
Dominari Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.88% below the high.
Loading market information…
NASDAQ · PHXM · USD
Stock price, earnings
Quote as of Mar 8, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
PHAXIAM Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 76.15% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PHAXIAM Therapeutics S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, which is currently undergoing Phase 3 clinical trials for advanced pancreatic cancer (second-line treatment) and Phase 2 studies for triple-negative breast cancer and relapsed acute lymphoblastic leukemia. Additionally, PHAXIAM is advancing a range of phage-based therapies designed to combat severe, drug-resistant bacteria. These pathogens are responsible for over two-thirds of nosocomial (hospital-acquired) infections that resist conventional treatments, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Established in 2004 and headquartered in Lyon, France, the company was previously known as ERYTECH Pharma S.A. before adopting its current name, PHAXIAM Therapeutics S.A., in June 2023.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$1.72-$0.03 (-1.71%)
Dominari Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.88% below the high.
$0.37-$0.01 (-2.12%)
Elevation Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.19% below the high.
$3.07+$0.29 (+10.43%)
MEI Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.89% below the high.
$13.60-$2.51 (-15.58%)
Pieris Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.07% below the high.
$1.21+$0.02 (+1.68%)
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.85% below the high.
$0.57-$0.26 (-30.77%)
Kineta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.34% below the high.
CA$8.75-CA$0.25 (-2.78%)
COSCIENS Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.9% below the high.
$0.30+$0.00 (+0.66%)
Traws Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.62% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
